Merck "good" cholesterol drug meets trial goals

VIENNA, Sept 2 (Reuters) Merck&Co's combination pill to raise ''good'' HDL cholesterol with less facial flushing -- a common side effect of HDL drugs -- met its main goals in a late-stage test, researchers said today.

Merck believes the favourable results should sway patients, who now shun HDL-boosting drugs because of bothersome flushing, to stick with treatment that may cut their risk of heart attacks and other cardiovascular problems.

Analysts reckon that could make Cordaptive, which may get to market in 2008, an eventual multibillion-dollar-a-year seller.

But Steven Nissen, a top US cardiologist at the Cleveland Clinic, said the drug reduced flushing less than he had hoped and there might be safety questions, given its mode of action.

The two-in-one drug contains an extended-release form of the vitamin niacin to raise levels of HDL, plus laropiprant to stop flushing, a dilation of blood vessels that causes redness and an unpleasant burning sensation on the neck and face.

HDL is considered ''good'' because it acts like a garbage truck, removing excessive levels of artery-clogging LDL cholesterol from the bloodstream.

The Phase III trial reported at the annual European Society of Cardiology congress in Vienna involved 1,613 at-risk patients, of whom about 65 per cent were already taking statins.

Patients started out taking either 1 gram of Cordaptive daily, one gram of extended-release niacin alone or a placebo. After four weeks, those receiving Cordaptive and niacin alone doubled their doses to two grams for another 20 weeks.

Levels of LDL cholesterol fell an average 19 per cent during weeks 12 to 24 among patients taking two gram-doses of Cordaptive, compared with a fall of 0.5 per cent among those on placebos.

Average HDL levels rose 19 per cent in the Cordaptive group, versus a 1.2 per cent drop in the placebo group. Moreover, triglyceride levels fell 22 per cent, compared with an increase of 3.6 per cent with placebo.

EFFICACY MATCHES NIASPAN Dr Richard Pasternak, a senior Merck research official who helped conduct the trial, said the findings could trigger a rethink of treatment strategies.

''It's a breakthrough because this comprehensive lipid therapy has not been available or achievable by most people. Physicians are reluctant to prescribe the agent (niacin) and patients are reluctant to take it,'' he said in an interview.

Importantly, the beneficial effects of Cordaptive matched those commonly seen with Niaspan -- a widely used niacin drug sold by Abbott Laboratories.

Although Niaspan was not used in the Merck trial, Pasternak said the cholesterol outcomes were ''in exactly the same range'', with Cordaptive avoiding the significant flushing problem.

An estimated 69 per cent of patients given the initial one gram doses of Cordaptive reported either no flushing or mild flushing symptoms during the first week of treatment, compared to 44 per cent of those who received extended-release niacin alone.

The frequency of moderate or greater flushing by week 24 was 0.2 days per week among patients taking 2-gram doses of Cordaptive or placebos, compared with 0.7 days among those given niacin without the flushing inhibitor.

The difference meant more than twice as many patients on niacin alone discontinued treatment because of flushing than patients taking Cordaptive -- 22 per cent versus 10 per cent.

Two-gram doses of niacin are typically needed to boost HDL levels but flushing problems mean the most common prescribed dose is only half a gram.

The Cleveland Clinic's Nissen said the new drug could help patients who were particularly intolerant but said others were able to tolerate niacin if dosing was increased slowly.

As a result, he told reporters he viewed Cordaptive as an incremental advance rather than a breakthrough.

Nissen also said the regulators were likely to look closely at safety issues, since the anti-flushing agent works by blocking a receptor to the hormone prostaglandin.

There were four treatment-related serious adverse events in the Cordaptive study, including one pregnancy miscarriage.

Merck said last week US regulators will likely decide by the second quarter of 2008 whether to approve Cordaptive.

If cleared it will compete head-on with Abbott's Niaspan, which had second-quarter sales of 0 million -- and Merck is banking on its anti-flushing power to give it a commercial edge.

REUTERS PDT PM1645